1. Search Result
Search Result
Results for "

PAMPA

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

2

Screening Libraries

1

Fluorescent Dye

2

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D2060

    Fluorescent Dye Others
    ATTO 740 is a near-infrared dye (Ex/Em: 740/764 nm). ATTO 740 can be conjugated with the Cetuximab antibody (HY-P9905) .
    ATTO 740
  • HY-146341

    FAAH MAGL Neurological Disease
    FAAH-IN-5 (Compound 7) is a relative selective, irreversible fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 10.5 nM. FAAH-IN-5 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .
    FAAH-IN-5
  • HY-146342

    FAAH MAGL Neurological Disease
    FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC50 values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .
    FAAH/MAGL-IN-3
  • HY-144285

    CXCR HIV Inflammation/Immunology
    CXCR4 antagonist 4 is a potent, orally active CXCR4 antagonist (IC50=24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC50=7 nM) .
    CXCR4 antagonist 4
  • HY-117776

    ICMT Cancer
    CAY10677 (compound 15) is a potent ICMT inhibitor that inhibits cancer cell proliferation. CAY10677 has good PAMPA penetration .
    CAY10677
  • HY-149729

    ICMT Cancer
    ICMT-IN-53 (compound 12) is an ICMT inhibitor (IC50=0.96 μM) with PAMPA permeability and antiproliferative activity. ICMT-IN-53 inhibits the proliferation of MDA-MB-231 and PC3 with IC50s of 5.14 μM and 5.88 μM, respectively .
    ICMT-IN-53
  • HY-168241

    Cholinesterase (ChE) 5-HT Receptor Infection
    Flucopride (Compound 4a) is an AChE inhibitor (IC50: 24 nM), and a partial 5-HT4R agonist (Ki: 9.6 nM for (h)5-HT4R). Flucopride promotes the non-amyloidogenic processing of APP in COS-7 transiently expressing (h)5-HT4R (EC50: 23.0 nM). Flucopride may has good gastrointestinal track (GIT) penetration, and blood-brain barrier (BBB) cross-membrane penetration (PAMPA assay) .
    Flucopride
  • HY-181711

    NO Synthase Neurological Disease Cancer
    nNOS-IN-6 is a human neuronal nitric oxide synthase (hnNOS) inhibitor with a human hnNOS Ki of 16 nM, ~1800-fold selectivity over human eNOS, ~2900-fold selectivity over human iNOS, and a rat nNOS Ki of 34 nM.nNOS-IN-6 exhibits high effective permeability in PAMPA-BBB assays, crosses the blood-brain barrier, and shows sustained systemic exposure, low clearance, and robust brain penetration in mouse in vivo pharmacokinetic studies.nNOS-IN-6 can be used for the research of neurodegenerative diseases, melanoma .
    nNOS-IN-6
  • HY-P11621

    E1/E2/E3 Enzyme Cancer
    JWP24 is the first cell membrane-permeable peptide inhibitor of MAGE-A4, with an IC50 of 200 nM against human MAGE-A4. JWP24 binds to intracellular targets while retaining binding activity, disrupts the interaction between MAGE-A4 and RAD18, and does not induce cytotoxicity at effective concentrations. JWP24 is applicable for cancer-related research .
    JWP24
  • HY-181710

    mTOR PI3K Cancer
    LASSBio-2337 is a dual pan-PI3K/mTOR inhibitor with an mTOR IC50 of 5.8 μM.LASSBio-2337 functionally modulates mTOR and all PI3K isoforms.LASSBio-2337 acts as a cytotoxic agent in leukemia cells, including multidrug-resistant populations.LASSBio-2337 spares nontumor human peripheral blood mononuclear cells.LASSBio-2337 displays moderate PAMPA-GIT permeability.LASSBio-2337 shows low metabolic stability in rat liver microsomes.LASSBio-2337 is aqueous insoluble.LASSBio-2337 can be used for the research of acute lymphoblastic leukemia, chronic myelogenous leukemia, breast cancer .
    LASSBio-2337
  • HY-181553

    PROTACs Epigenetic Reader Domain Cancer
    PROTAC BRD4 Degrader-44 (compound 2a) is a PROTAC degrader targeting BRD4 with passive membrane permeability. PROTAC BRD4 Degrader-44 maintains stability within 6 hours in medium supplemented with 10% FBS. PROTAC BRD4 Degrader-44 shows a trend of increasing intracellular accumulation within 6 hours, indicating reduced efflux .
    PROTAC BRD4 Degrader-44

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: